Volume 10, Number 5—May 2004
Dispatch
Mycobacterium africanum Cases, California
Table 2
Patient | No. of copies of IS6110 (bands) | Spoligo-typing pattern missing spacers 8,9,39? | OxyR285a | Codon katG463 sequenceb | Presence of RD9 deletion? | PZA susceptibilityc | Niacin pro-duction | Nitratereduc-tiond | Major site of disease | Birth country |
---|---|---|---|---|---|---|---|---|---|---|
A |
10 |
Yes |
G |
CTG |
Yes |
S |
+ |
3+ |
Lung |
South Africa |
B |
3 |
Yes |
G |
CTG |
Yes |
S |
N.D.e |
N.D. |
Lung |
Ivory Coast |
C |
9f |
Yes |
G |
CTG |
Yes |
S |
N.D. |
N.D. |
Lung |
South Africa |
D |
11 |
Yes |
G |
CTG |
Yes |
S |
+ |
4+ |
Lung |
Vietnam |
E | 9 | Yes | G | CTG | Yes | S | + | 3+ | Pancreas | USA |
aIsolates of M. bovis do not have G at this site.
bCTG is found in M. bovis and M. africanum, but not in most strains of M. tuberculosis.
cS, susceptible; PZA, pyrazinamide.
d3+ and 4+ reactions are considered positive.
eND, not done (because the culture lost viability).
fRestriction fragment length polymorphism patterns for isolates from patients C and E were identical.
Page created: June 14, 2011
Page updated: June 14, 2011
Page reviewed: June 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.